

OVERVIEW

Report of the Supervisory Board

The 5,000 employees of QIAGEN – known as QIAGENers – are the reason for our success. The members of the Supervisory Board wish to thank all QIAGENers for their contributions during 2018 toward achieving our vision of making improvements in life possible. We would also like to thank our shareholders, customers, business partners and other stakeholders for honoring QIAGEN with their continued collaboration and trust.

2018 performance achieves full-year goals

A key role of the Supervisory Board is to monitor the performance and progress of QIAGEN's business on a regular basis, and this was done during the course of 2018 with detailed written and oral reports from the Managing Directors, members of the Executive Committee and other senior leaders.

We were pleased with the achievements of QIAGEN in 2018, delivering a performance in line with our outlook for net sales growth and exceeding our target for adjusted earnings per share. Our teams made outstanding progress on creating what we believe is one of the most dynamic and disruptive portfolios of Sample to Insight solutions for molecular testing. QIAGEN's growth initiatives are moving ahead well, and the efforts of our employees in 2018 have created a solid foundation for further growth in 2019 and the coming years. We support the strategy of QIAGEN to deliver on growth plans and expand the leadership position in molecular testing across the continuum from life sciences research to clinical healthcare.

Composition of the Supervisory Board and Managing Board

The composition of the Supervisory Board changed during 2018 with the retirement of Prof. Dr. Manfred Karobath. As announced in early 2018, Dr. Håkan Björklund was chosen by the Supervisory Board as the new Chairman after the Annual General Meeting in June 2018.

The members of the Supervisory Board would like to express their deepest appreciation for the contributions of Prof. Karobath to QIAGEN during his 18 years on the Supervisory Board, having served as a source of wisdom and insight, as well as contributing his extensive experience in the pharmaceuticals and life sciences industries. He was an essential contributor in helping QIAGEN to develop truly innovative products and solutions that have helped QIAGEN make progress toward achieving its vision of making improvements in life possible.

All current members of the Supervisory Board are expected to stand for re-election at the upcoming Annual General Meeting in June 2019. All members, with the exception of Dr. Metin Colpan and Ms. Elizabeth E. Tallett have served in the Supervisory Board for less than eight years as recommended by the Dutch Corporate Governance Code.

QIAGEN values the profound industry experience of Dr. Colpan and Ms. Tallett for their in-depth knowledge, and supports their reappointments.

The target profile of the Supervisory Board can be found on QIAGEN's website, and the current composition fully complies with this profile. Further information on the individual members of the Supervisory Board, such as gender, age, nationality and other positions relevant to the performance of its duties as Supervisor Board member, date of initial appointment and current term of office is set forth in the Corporate Governance and Compensation overview.

QIAGEN has a commitment to developing a diverse leadership team, with a broad range of backgrounds, experience, skills and capabilities. In nominating candidates, QIAGEN is committed to increasing diversity while pursuing individuals to join QIAGEN with a unique blend of scientific and commercial expertise and experience that will contribute to our future business success. Management development programs support the career advancement of leaders regardless of gender and other factors. As a result, a number of women are in key leadership roles around the world, and QIAGEN currently has 28% of management roles held by women. In line with this commitment, the Supervisory Board continues to take diversity into account when proposing members for election or re-election without compromising QIAGEN's commitment to hiring the best individuals for positions without any discrimination. The current governance structure has led to the size of the Managing Board of two members, so achieving a diversity goal as measured solely by a percentage of overall membership is difficult to achieve. At the same time, QIAGEN has significantly increased the diversity of its senior leadership team and will continue to do so in the future.

Principal topics discussed by the Supervisory Board

As empowered by the Dutch Corporate Governance Code, the Supervisory Board devoted considerable time during 2018 to discussing and assessing QIAGEN's corporate strategy, main risks and opportunities, and an annual assessment by the Managing Board of the design and effectiveness of internal risk management and control systems as well as any significant changes in them. In addition, the Supervisory Board discussed and reviewed the functioning of its committees and individual members, its current composition, competence, succession schedule and desired profile in various meetings and through written surveys.

The Supervisory Board met five times during 2018 with attendance of all Supervisory Board members in all meetings and regular attendance of the members of the Managing Board for certain agenda items. The Supervisory Board also met to review and discuss agenda items in the absence of the Managing Board members, such as performance and strategy as well as to discuss compensation matters. Information about the Supervisory Board members, including positions held on other boards, is included in the Corporate Governance and Compensation overview. All members of the Supervisory Board had adequate time available to give sufficient attention to the concerns of the company. The Supervisory Board further discussed the performance of the Managing Board and concluded that it and the Managing Board were functioning properly.

Committees of the Supervisory Board

The Supervisory Board has established an Audit Committee (Chair Mr. Lawrence Rosen), a Compensation Committee (Chair Ms. Elizabeth Tallett), a Selection and Appointment Committee (Chair Dr. Björklund), and a Science and Technology Committee (Chair Dr. Metin Colpan) from among its members. The Supervisory Board reserves the right to establish other committees as deemed beneficial, and has approved charters under which each of these committees operates (charters are available on our website at www.QIAGEN.com). The deliberations and findings of the committees were reported by the committee chairs to the Supervisory Board in its meetings on a regular basis. All committee members attended all committee meetings in 2018 physically or by phone. Further detailed information on the composition of the Supervisory Board and its committees, the number of committee meetings held in 2018 and the main topics of discussion, the remuneration of its members, as well as other information on the Supervisory

Board, can be found in the Corporate Governance and Compensation overview, which is an integral part of this Annual Report.

Through its Compensation Committee, the Supervisory Board executed and monitored compliance with the Remuneration Policy approved at the Annual General Meeting held on June 25, 2014. Compensation of Managing Board members consists of a fixed salary and variable components. Variable compensation includes one-time and annual payments linked to business performance (bonuses) as well as long-term incentives, such as share-based compensation, and pension plans. The Remuneration Policy and the various aspects of compensation, including the detailed remuneration of individual Managing Board members, are described in the Remuneration Report, which is available on QIAGEN's website. Information on QIAGEN's activities was communicated by the Managing Board to the Supervisory Board through regular meetings and business reports.

Corporate governance

All members of the Supervisory Board fulfill the independence criteria as defined by the Dutch Corporate Governance Code. The Supervisory Board follows the principle of increasing shareholder value as the members represent the interests of all stakeholders, including shareholders, and has always pursued the highest standards in Corporate Governance.

QIAGEN is committed to a corporate governance structure that best suits its business and stakeholders, and that complies with relevant rules and regulations. QIAGEN has endorsed since 1997 the recommendations made in the report of the Netherlands Committee on Corporate Governance, which was replaced by the Dutch Corporate Governance Code effective January 1, 2004. The Dutch Code was last amended on December 8, 2016 and is applicable as from January 1, 2017. Our policy is to follow the guidelines of Good Practice of Corporate Governance as described in the Dutch Corporate Governance Code, although some minor deviations may result from the impact of factors such as legal requirements imposed on QIAGEN or industry standards.

QIAGEN's common shares are registered and traded in the U.S. on the New York Stock Exchange as of January 2018 (formerly on the NASDAQ Global Select Market) and in Germany on the Frankfurt Stock Exchange in the Prime Standard segment. Shareholders in Europe and the U.S. hold the majority of common shares. As a result of these listings for its Global Shares, QIAGEN is subject to the rules regarding Corporate Governance set by the NYSE. Additionally, QIAGEN provides detailed disclosure in the Corporate Governance and Compensation overview regarding compliance with the Dutch Corporate Governance Code.

QIAGEN believes all of its operations are carried out in accordance with legal frameworks, including Dutch Corporate Law, U.S. laws and regulations, EU regulations and laws of the German capital market.

Financial statements and audits

In this Annual Report, the financial statements for 2018 are presented as prepared by the Managing Board, audited by KPMG (Independent Registered Public Accounting Firm). We examined the financial statements, the proposal for the use of the distributable profit, the consolidated financial statements and the management report. We have no objections, thus we concur with the results of the audit, and it has been approved by the Supervisory Board. In closing, the Supervisory Board would like to again thank all QIAGEN employees for the outstanding performance and commitment during 2018.

Venlo, the Netherlands, March 2019

The Supervisory Board:

Dr. Håkan Björklund

Chairman of the Supervisory Board

OVERVIEW

The Executive Committee



Peer M. Schatz
Chief Executive Officer



Thierry Bernard
Senior Vice President Molecular
Diagnostics Business Area



Dr. Barthold Piening
Senior Vice President, Head of Global
Operations



Dr. Annette Koch
Senior Vice President and Chief
Human Resources Officer



Manuel O. Méndez
Senior Vice President Global
Commercial Operations



Roland Sackers
Chief Financial Officer



Dr. Thomas Schweins
Senior Vice President, Life Science
Business Area



Dr. Jonathan Sheldon
Senior Vice President, Bioinformatics
Business Area

Peer M. Schatz

Chief Executive Officer, Managing Director

Joined QIAGEN in 1993, and has been Chief Executive Officer since January 1, 2004. He was Chief Financial Officer between 1993 and 2003 and became a member of the Managing Board in 1998. Mr. Schatz was previously a partner in a private management buyout group in Switzerland, worked in finance and systems positions at Sandoz AG and Computerland, and participated in the founding of start-up companies in the computer and software trading industry in Europe and the United States.

Mr. Schatz graduated from the University of St. Gallen, Switzerland, with a Master's degree in Finance in 1989 and obtained an M.B.A. in Finance from the University of Chicago Graduate School of Business in 1991. Mr. Schatz served as a member of the German Corporate Governance Commission from 2002 to 2012. He is a board member of AdvaMedDx, a U.S. trade association that leads the effort to advance medical technology in order to achieve healthier lives and healthier economies around the world and ALDA (the Analytical, Life Science and Diagnostics Association), a trade association of developers and suppliers in these fields. He is also Managing Director of PS Capital Management GmbH.

Thierry Bernard

Senior Vice President Molecular Diagnostics Business Area

Joined QIAGEN in February 2015 to lead QIAGEN's growing presence in Molecular Diagnostics, the application of Sample to Insight solutions for molecular testing in human healthcare. Mr. Bernard previously worked at bioMérieux, where he served in roles of increasing responsibility for 15 years, most recently as Corporate Vice President, Global Commercial Operations, Investor Relations and the Greater China Region. Prior to joining bioMérieux, he served in management roles in multiple international environments. Mr. Bernard is a member of the Boards of Directors of three privately held U.S. companies, First Light Biosciences, HepatoChem and more recently, Daktari Diagnostics, where he also served as CEO. He has earned degrees from Sciences Po (Paris), Harvard Business School, London School of Economics and the College of Europe and is a member of French Foreign Trade Advisors.

Dr. Barthold Piening

Senior Vice President, Head of Global Operations

Joined QIAGEN in December 2018 as Senior Vice President, Head of Global Operations, and a member of the Executive Committee. Dr. Piening has more than 30 years of experience in strategy and operations in the pharmaceutical, life science and medical device industries. Prior to joining QIAGEN, he was Executive Board member in charge of production and technology for the German pharma company STADA. Dr. Piening had previously served as Chief Operating Officer and EC member of Acino Pharma, and before that as Head of Global Operations for Takeda Pharmaceuticals International. Earlier, he had roles of increasing responsibility at Byk Gulden, ALTANA Pharma and Nycomed. After studying pharmaceutical sciences at the University of Kiel in Germany and the University of Wales in Cardiff, U.K., he earned a degree in Pharmaceutics with Approbation and a Ph.D. in Pharmaceutical Chemistry from the University of Kiel. He also earned an MBA at WHU-Vallendar in Germany and Northwestern University in the United States.

Dr. Annette Koch

Senior Vice President and Chief Human Resources Officer

Joined QIAGEN in 2018 as Senior Vice President and Chief Human Resources Officer, overseeing all aspects of QIAGEN's global Human Resources function. She came to QIAGEN from Eppendorf AG, where she had been Vice President Human Resources since 2013, supporting about 3,200 employees in 26 countries. Previously, she held roles of increasing responsibility from 2003 to 2013 with Boehringer Ingelheim. Dr. Koch started her career at The

Boston Consulting Group in Düsseldorf, working on projects in the pharmaceutical and chemical industries. She earned a Ph.D. in Organic Chemistry from the University of Hannover, and during her graduate studies also worked in the University of Southern California laboratory of Prof. George Andrew Olah, who had won the Nobel Prize in Chemistry in 1994.

Manuel O. Méndez

Senior Vice President Global Commercial Operations

Joined QIAGEN in October 2014 as Senior Vice President, Global Commercial Operations, leading sales and marketing worldwide. Mr. Méndez has 25 years of experience in diagnostics and life sciences, most recently as Executive Vice President Americas for bioMérieux from 2010 – 2014. Previously he served in sales, marketing and general management roles with Abbott Laboratories, Thermo Fisher Scientific and OraSure Technologies – with leadership positions in the United States, Latin America, Europe and Asian markets. He is on the advisory board of 908 Devices, a maker of point-of-need chemical analyzers. Mr. Méndez received a B.S. in biomedical Engineering from Boston University and an M.B.A. from Northwestern University Kellogg School of Management.

Roland Sackers

Chief Financial Officer

Joined QIAGEN in 1999 as Vice President Finance and has been Chief Financial Officer since 2004. In 2006, Mr. Sackers became a member of the Managing Board. Between 1995 and 1999, he served as an auditor with Arthur Andersen Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft. Mr. Sackers earned his Master Degree in Business Administration (Diplom-Kaufmann) from the University of Münster, Germany. He is a former member of the Supervisory Board and Audit Committee of IBS AG and a former member of the board of directors of Operon Biotechnologies, Inc. Mr. Sackers is a board member of the industry association BIO Deutschland. He was previously a non-executive director and chair of the audit committee of Immunodiagnostic Systems Holdings PLC (IDS) from 2011 - 2018, a publicly listed producer of immunological tests for research and diagnostic applications in the United Kingdom.

Dr. Thomas Schweins

Senior Vice President, Life Science Business Area

Joined QIAGEN in 2004 as Vice President Corporate Strategy and was appointed Vice President Marketing & Strategy in 2005, where he was deeply involved in managing the global business toward Life Science customers. In late 2011, Dr. Schweins has assumed responsibility for Human Resources, and took over the leadership of the Life Science Business Area in 2017. Dr. Schweins came to QIAGEN from The Boston Consulting Group. He previously worked as Technology Manager, and later as an Assistant to the Management Board at Hoechst / Aventis. Dr. Schweins earned an M.Sc. Degree in Biochemistry from the University of Hanover. He obtained his Ph.D. at the Max Planck Society and received an M.Sc. from the University of Southern California in Los Angeles, where he studied Business Administration and Chemistry.

Dr. Jonathan Sheldon

Senior Vice President, Bioinformatics Business Area

Joined QIAGEN in 2018 as Senior Vice President, Bioinformatics Business Area. He leads QIAGEN's growing presence in bioinformatics, enabling customers to transform raw data from biological samples into valuable molecular insights. Dr. Sheldon came to QIAGEN from Oracle, where he was Global Vice President leading Oracle's Healthcare business globally in the Health Sciences Global Business Unit and served on the executive committee. Previously, he established the bioinformatics group and served as Head of Bioinformatics at Roche (UK) Pharmaceuticals, as well as providing leadership in software firms serving the life science and healthcare sectors. He

serves on the Board of Directors of the Drug Information Association (DIA). He received his B.Sc. in Biochemistry and Molecular Biology from the University of Manchester, and his Ph.D. in Biochemistry and Molecular Biology from the University of Cambridge.

OVERVIEW

Common Shares

QIAGEN's common shares significantly appreciated in U.S. and European markets in 2018, outperforming broad markets and industry peers on average. Strategic initiatives to accelerate growth and profitability with a dynamic and disruptive portfolio of Sample to Insight solutions delivered improved results. We thank shareholders for their support. QIAGEN's senior executives and Investor Relations team are recognized for proactive, transparent communications with the financial community.

Market Environment

Stock markets globally stumbled in 2018 after a strong year in 2017. During 2018, investors reacted to concerns about global trade relationships, including U.S.-China trade talks and the United Kingdom's negotiations to exit the European Union. Economic indicators in key regions including Europe and emerging markets pointed to slowdowns, while geopolitical developments and a shift toward normalizing monetary policy also were concerns in 2018.

As benchmarks, the S&P 500 index in the United States finished down 6.2% in 2018. The DAX index of the 30 largest companies in Germany fell 18.3% during the year, and Germany's TecDAX, of which QIAGEN is a member, declined 3.1% for the year.

Meanwhile, the molecular diagnostics and life science tools segment continued to grow in 2018. Expanding use of new molecular testing applications such as next-generation sequencing, liquid biopsies and epigenetics helped drive the market for instruments and consumables in research. Adoption of molecular technologies in healthcare continued to grow for precision medicine in oncology, infectious disease detection and diagnosis of rare diseases. Funding for academic research remained cautious, and healthcare faced continued uncertainty in reimbursement and government policies. QIAGEN delivered net sales growth at a solid single-digit growth at constant exchange rates (CER) in 2018 and improved profitability. QIAGEN's sales grew across all regions in 2018 and were led by sales in the Molecular Diagnostics, Academia and Pharma customer classes, fueled by differentiated solutions including the QuantiFERON latent TB test, next-generation sequencing technologies, the QIASymphony automation system and QIAGEN's Precision Medicine portfolio of companion diagnostic partnerships with pharma companies. QIAGEN continues to invest in its differentiated portfolio, allocating resources to sustain sales growth while improving profitability, enhancing shareholder value and maintaining flexibility.

Global shares listed in the U.S. and Europe

QIAGEN's global shares have been registered and traded in the United States since 1996, and were transferred to the New York Stock Exchange effective January 10, 2018, after trading on NASDAQ markets since the initial public offering (IPO). These global shares have also traded in Germany on the Frankfurt Stock Exchange since 1997, and

the Prime Standard segment since its launch in 2003. The dual listing of global shares on NYSE and the Frankfurt exchange offers advantages for QIAGEN, our shareholders and employees since this global presence increases the potential market opportunity to attract investors, particularly those in the U.S. that can only invest in U.S. dollar-denominated investments, and enhances liquidity. Unlike American Depositary Receipts (ADRs), QIAGEN's global shares provide equal rights for all shareholders and can be traded on either exchange, in U.S. dollars or euros.

Share Price and Liquidity

QIAGEN's common share price gained in 2018, climbing more than 11% in U.S. dollars to \$34.45 on the NYSE and nearly 13% in euros to EUR 29.68 on the Frankfurt Stock Exchange. Our common shares continued to offer high liquidity, with average daily trading volume during 2018 of approximately 1.5 million shares (0.99 million on the NYSE and other U.S. trading venues, and 0.53 million on the Frankfurt Stock Exchange (XETRA) and other German exchanges). QIAGEN continued its commitment to disciplined capital allocation. Under a commitment announced in January 2018 to return \$200 million to shareholders, a total of 3.4 million shares had been repurchased through January 2019 on the Frankfurt Stock Exchange at a volume-weighted average price of EUR 31.37 per share for EUR 108.0 million (approximately \$124 million at current exchange rates). As of December 31, 2018, the free float, which affects weighting of QIAGEN shares in various indices, was approximately 97%.

Index Membership

QIAGEN is a constituent in various European, U.S. and global stock indices, some of which serve as benchmarks or investment universes for mutual funds and exchange traded funds. QIAGEN ranks as one of the leading components by market capitalization in Germany's TecDAX index, which includes the 30 largest German technology companies not in the benchmark DAX index. In September 2018, QIAGEN shares were added to Germany's MDAX index, which tracks the next 60 largest companies on the German stock market after the 30 largest stocks in the DAX index. QIAGEN also is a member of the Russell 3000 index, which measures performance of the 3,000 largest U.S. companies, and the Russell 1000, a subset with the largest 1,000 U.S. securities. QIAGEN shares also are included in other stock market indexes such as the MSCI Europe, EMU and EAFE indexes.

Shareholder Structure

QIAGEN has a truly global investor base comprised of more than 400 identified institutional investors distributed around the world, including about one half in North America, about one-third in Europe and the remaining shares in the Asia-Pacific/Japan region. Members of the Managing Board and the Supervisory Board in total held about 3% of QIAGEN's outstanding common shares at the end of 2018.

Annual Shareholders' Meeting

At the 2018 Annual Shareholder Meeting on June 19, 2018, in Venlo, the Netherlands, shareholders voted in favor of all resolutions proposed by the Board of Directors, in many cases with majorities above 95% of shares present at the meeting. Shareholders present or represented at the meeting held approximately 157.4 million shares, or 68% of the approximately 230.8 million issued shares of QIAGEN as of the record date for the meeting. Details of attendance and voting results are available at <https://corporate.QIAGEN.com>.

Investor Relations and Engagement with Shareholders

QIAGEN is committed to offering shareholders, analysts and communities around the world transparent, comprehensive and readily accessible information on our vision, mission and strategy, as well as performance and future prospects.

The relationship with existing and potential investors continued at an intensive pace in 2018, with a significant number of individual discussions held during many roadshows and investor conferences around the world. Many investors and analysts made use during 2018 of the opportunity to inform themselves about QIAGEN in personal meetings at our sites in Hilden, Germany; Germantown, Maryland; Redwood City, California; and Singapore.


In 2018, QIAGEN’s efforts to address the needs of the financial community were recognized by DIRK (the association for Investor Relations in Germany) and Extel, ranking QIAGEN among the top companies, senior executives and IR professionals compared with all TecDAX companies, as well as among European medtech sector companies.

Approximately 25 analysts from international brokerages followed QIAGEN in 2018, with analysts based in the United States, France, Germany and the United Kingdom.

QIAGEN Share Price Development and Average Trading Volume – NYSE 2018⁽¹⁾

	2018
Year-end price	\$ 34.45
High	\$ 39.45
Low	\$ 30.78
Average daily trading volume (in million shares)	0.99


⁽¹⁾ QIAGEN was traded on the NASDAQ market through January 9, 2018



QIAGEN Share Price Development and Average Trading Volume – Frankfurt Stock Exchange (XETRA) 2018

2018

Year-end price	€ 29.68
High	€ 34.05
Low	€ 25.22
Average daily trading volume (in million shares)	0.53



Key Share Data

2018

Year-end market capitalization (in \$ million)	7,769
Year-end market capitalization (in € million)	6,693

Source: QIAGEN Shareholder ID

United States	48%
Germany	8%
France	7%
England	10%
Other	2%
Non-Institutional	25%

Source: QIAGEN Shareholder ID

Source: QIAGEN Shareholder ID

GARP	23%
Value	13%
Index	19%
Growth	14%
Other	5%
Non-Institutional	25%

Source: QIAGEN Shareholder ID